Discovery of Small Molecule Agonist of Gonadotropin-Releasing Hormone Receptor (GnRH1R)

The gonadotrophin-releasing hormone (GnRH) is a central
regulator
of the human reproductive system and exerts physiological effects
by binding to GnRH1R. The GnRH–GnRH1R system is a promising
therapeutic target for the maintenance of reproductive function. There
are several GnRH1R agonists on the market, but like GnRH, they are
all peptide compounds and are limited by their way of administration
(subcutaneous or intramuscular injection). To date, no published GnRH1R
small molecule agonists have been reported. In this paper, the HTRF-based
screening method has been used to screen our in-house chemical library,
and we found and confirmed CD304 as a hit compound. Subsequently,
structure optimization led to the discovery of compound 6d, exhibited with a certain GnRH1R activation activity (EC50: 1.59 ± 0.38 μM). Further molecular dynamics simulation
experiments showed that 6d can well bind to the orthosteric
site of GnRH1R through forming a hydrogen-bonding interaction with
Y2836.51. Binding of 6d further induces conformational
changes in TM6 and TM7, promoting the formation of a continuous water
channel in GnRH1R, thereby promoting GnRH1R activation. This well-characterized
hit compound will facilitate the further development of novel small
molecule agonists of GnRH1R.